- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology | Clinical
Next-Generation Treatments for Blood Cancers: Improved Outcomes in the Forecast
June 16, 2022
The excitement surrounding advances and improved outcomes in very difficult-to-treat diseases is palpable. Yet the complexities of these therapies also bring their own complications.
Adaptive NK Cell Platform Shows Safety for Hematological Malignancies
June 11, 2022
Jeffrey S. Miller, MD, discusses the findings of a study of the Tri-Specific Killer Engager platform for the activation of natural killer cells for the treatment of refractory acute myeloid leukemia and other cancers.
Hyper-CVAD With Blinatumomab and Inotuzumab Shows High Efficacy in Ph-Negative B-Cell ALL
June 04, 2022
The probability of minimal residual disease negativity and complete remission in patients who received hyper-CVAD with blinatumomab and inotuzumab is higher compared with hyper-CVAD and blinatumomab alone.
Roundtable Discussion: Early Treatment Options and Policies Discussed for Acute GVHD
June 03, 2022
During a Targeted Oncology case-based roundtable event, Pashna N. Munshi, MD, discussed the case of a patient who developed maculopapular rash 22 days following hematopoietic stem cell transplantion.
McKinney Compares Therapeutic Agents in Later-Line DLBCL
May 27, 2022
The case of a 59-year-old African American women with clear cell renal cell carcinoma was the topic of discussion among Eric Jonasch, MD and 7 peers during a case-based roundtable event.
FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia
May 20, 2022
The FDA has granted approval to azacitidine for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia following positive phase 2 research.
Simplifying CAR T-Cell Manufacturing for R/R B-Cell Non-Hodgkin’s Lymphoma
May 19, 2022
Manali Kamdar, MD, MBBS, discusses the background on a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell non-Hodgkin’s lymphoma.
FDA Okays Study of Bexmarilimab in Hematologic Malignancies
May 19, 2022
The FDA allows for an investigational new drug application for the start of the BEXMAB study of bexmarilimab plus standard of care therapy in various hematologic malignancies.
Stem Cell Transplant Holds its Position as Upfront Treatment for Hematologic Malignancies
May 10, 2022
In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed the evolving role of stem cell transplant in hematologic malignancies as CAR T-cell therapies begin to reshape treatment landscapes.
Next Generation Treatments for Blood Cancers: Improved Outcomes in the Forecast
May 09, 2022
As these new techniques evolve and we adjust conditioning regimens, induction timing and dosing levels, as well as introducing different drug combinations, we are very hopeful that we will continue to see improved outcomes for hematologic malignancies, says Guenther Koehne, MD, PhD.